Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma - 18/04/17
, Zuxu Yao, PhD b, David Polsky, MD, PhD c, d, Burkhard Jansen, MD b, Klaus Busam, MD e, Jonhan Ho, MD f, Mary Martini, MD a, Laura K. Ferris, MD, PhD fAbstract |
Background |
Clinical and histopathologic assessment of pigmented skin lesions remains challenging even for experts. Differentiated and accurate noninvasive diagnostic modalities are highly desirable.
Objective |
We sought to provide clinicians with such a tool.
Methods |
A 2-gene classification method based on LINC00518 and preferentially expressed antigen in melanoma (PRAME) gene expression was evaluated and validated in 555 pigmented lesions (157 training and 398 validation samples) obtained noninvasively via adhesive patch biopsy. Results were compared with standard histopathologic assessment in lesions with a consensus diagnosis among 3 experienced dermatopathologists.
Results |
In 398 validation samples (87 melanomas and 311 nonmelanomas), LINC00518 and/or PRAME detection appropriately differentiated melanoma from nonmelanoma samples with a sensitivity of 91% and a specificity of 69%. We established LINC00518 and PRAME in both adhesive patch melanoma samples and underlying formalin fixed paraffin embedded (FFPE) samples of surgically excised primary melanomas and in melanoma lymph node metastases.
Limitations |
This technology cannot be used on mucous membranes, palms of hands, and soles of feet.
Conclusions |
This noninvasive 2-gene pigmented lesion assay classifies pigmented lesions into melanoma and nonmelanoma groups and may serve as a tool to help with diagnostic challenges that may be inherently linked to the visual image and pattern recognition approach.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : biopsy, gene expression, histopathology, LINC00518, melanoma, noninvasive, preferentially expressed antigen in melanoma
Abbreviations used : LINC, PCR, PRAME, qRT, SSM
Plan
| Sponsored by DermTech Inc (La Jolla, CA) and supported by the IDP Foundation (Chicago, IL). |
|
| Disclosure: Drs Gerami, Polsky, and Ferris serve as consultants to DermTech Inc. Drs Yao and Jansen are employees of DermTech Inc. Drs Busam, Ho, and Martini have no conflicts of interest to declare. |
|
| Presented as a late-breaking presentation (abstract 3816) at the 74th Annual Meeting of the American Academy of Dermatology in Washington, DC, on March 4-8, 2016. |
Vol 76 - N° 1
P. 114 - janvier 2017 Retour au numéro
Article précédent
- Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center
- Haur Yueh Lee, Stephanie Fook-Chong, Hong Yi Koh, Tharmotharampillai Thirumoorthy, Shiu Ming Pang
- Variation among pathologists' treatment suggestions for melanocytic lesions: A survey of pathologists
- Kachiu C. Lee, Sue Peacock, Martin A. Weinstock, Ge Alice Zhao, Stevan R. Knezevich, David E. Elder, Raymond L. Barnhill, Michael W. Piepkorn, Lisa M. Reisch, Patricia A. Carney, Tracy Onega, Jason P. Lott, Joann G. Elmore
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?